Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on March 10, 2025. The filing reports the entry into a material definitive agreement and the completion of an asset acquisition involving the company's wholly owned subsidiary, Cyclacel Limited, which is currently in liquidation.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the transaction value for the asset purchase.
- Purchase Price: £250,000 (exclusive of VAT) for the acquisition of assets related to Plogosertib.
- Payment Terms: Cash consideration required for any future disposal of the assets.
Material Changes and Transaction Details
On March 10, 2025, Cyclacel Pharmaceuticals, Inc. entered into an Agreement for the Sale and Purchase of Certain Assets with Cyclacel Limited and its liquidators. The transaction involves:
- Assets Acquired: Certain assets related to Plogosertib (Plogo), a polo-like kinase 1 (PLK 1) inhibitor for the treatment of esophageal cancer and acute leukemia.
- Patent Rights: An accompanying Assignment of Patent Rights Agreement transferred all rights, title, and interest in specific patents related to Plogo to the parent company.
- Future Disposal Obligations: The Company agreed to dispose of the assets only for cash. If a subsequent disposal occurs, the Company must pay 50% of the surplus (defined as the difference between the sale price and the greater of £250,000 or £250,000 plus direct R&D costs) to Cyclacel Limited within 14 days.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard legal disclosures. The transaction is contingent upon the approval of the liquidators of Cyclacel Limited. The filing notes that certain confidential portions of the attached exhibits were omitted as they are not material or would be competitively harmful if disclosed.
Key Facts for Investor Verification
- Verify the status of Cyclacel Limited's liquidation and the role of liquidators Carrie James and James Hopkirk.
- Confirm the regulatory status and development stage of Plogosertib (Plogo) for esophageal cancer and acute leukemia.
- Review the full text of the Purchase Agreement (Exhibit 2.1) and Patent Assignment Agreement (Exhibit 10.1) to understand the definition of "direct costs" which impacts future surplus payments.
- Monitor the Company's cash position to ensure it can meet the £250,000 purchase price obligation.